Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Can DES Improve Diabetic Outcomes? Cardiologists Turn FREEDOM Fighters

This article was originally published in The Gray Sheet

Executive Summary

Drug-eluting stent trial and registry data suggest the technology is catching up with bypass surgery in reducing repeat revascularizations in diabetics, but researchers await clarity on the most elusive endpoint of all - survival

You may also be interested in...



Clinical Trials In Brief

ICD lead failures: About 40% of implantable defibrillator leads fail within eight years after implant, according to a study published April 30 on the Web site of Circulation, the journal of the American Heart Association. In the study at the Herzzentrum Ludwigshafen in Ludwigshafen, Germany, 990 patients implanted with a variety of ICD and lead models were followed for a median of 934 days. A total of 148 leads failed during the follow up. The failure rate increased with time after implantation, reaching 20% annually by the tenth year. Estimated survival rates at eight and five years were 60% and 85%, respectively. Previous studies have suggested that leads with a coaxial single lumen polyurethane insulated design such as Medtronic's Transvene 6936 and 6966 models are prone to failure and inappropriate shocks. Newer leads (after 1997) feature a multi-lumen design and silicone insulation intended to prevent degradation and injury from mechanical stress. However, Kleeman's study showed that the silicone insulation was also prone to failure and the overall survival rates for the older and newer designs were roughly the same at seven years following implantation...

Clinical Trials In Brief

ICD lead failures: About 40% of implantable defibrillator leads fail within eight years after implant, according to a study published April 30 on the Web site of Circulation, the journal of the American Heart Association. In the study at the Herzzentrum Ludwigshafen in Ludwigshafen, Germany, 990 patients implanted with a variety of ICD and lead models were followed for a median of 934 days. A total of 148 leads failed during the follow up. The failure rate increased with time after implantation, reaching 20% annually by the tenth year. Estimated survival rates at eight and five years were 60% and 85%, respectively. Previous studies have suggested that leads with a coaxial single lumen polyurethane insulated design such as Medtronic's Transvene 6936 and 6966 models are prone to failure and inappropriate shocks. Newer leads (after 1997) feature a multi-lumen design and silicone insulation intended to prevent degradation and injury from mechanical stress. However, Kleeman's study showed that the silicone insulation was also prone to failure and the overall survival rates for the older and newer designs were roughly the same at seven years following implantation...

Vulnerable Plaque, CABG Patients Would Expand Stent Candidate Pool

Interventional cardiology device makers are developing new patient populations now that drug-eluting stents are shown to virtually eliminate restenosis

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel